The Europe onychomycosis market is growing steadily, driven by rising prevalence of nail fungal infections, an aging population, and growing awareness about effective treatment options. Oral antifungals dominate the market, supported by topical agents, combination therapies, and emerging laser treatments.

Market growth is further fueled by technological advancements in drug formulations, improved delivery systems, and increasing patient education on nail health. Germany, France, and the UK are major contributors, with well-established healthcare systems and regulatory frameworks supporting market expansion.

Europe’s onychomycosis market is expected to witness sustained growth, underpinned by increasing diagnostic capabilities, treatment innovation, and enhanced patient access to healthcare solutions.